Digest Network Come funziona
Network
/
Società
Io
Non verificato

Ionis Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

75 comunicati stampa

Guarda tutti i comunicati
29/07/2026
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Biotecnologia
Farmaceutica
Cardiologia
Ionis reports second quarter 2026 financial results and highlights progress on key programs
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
15/07/2026
Salute
Biotecnologia
Farmaceutica
Cardiologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Ionis to hold second quarter 2026 financial results webcast
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
14/07/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/07/2026
Farmaceutica
Salute
Medicina - Varie
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
09/07/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Cardiologia
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/07/2026
Farmaceutica
Biotecnologia
Salute
Medicina - Varie
Industria
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/06/2026
Mercato del lavoro
Industria
Salute
Biotecnologia
Farmaceutica
Cardiologia
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
24/06/2026
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/06/2026
Mercato del lavoro
Salute
Biotecnologia
Farmaceutica
Cardiologia
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0